ChemLifeIntel
Access

Glycopyrrolate

TRACKED

Anticholinergic

CASHSN
THERAPEUTIC AREAS
MOLECULE INTELLIGENCE SNAPSHOTlive
14
Manufacturers monitored
38
Intelligence briefs
3
Active regulatory actions
₹2,800 Cr
Est. India export value

INTELLIGENCE

Showing 1 of 1 briefs for Glycopyrrolate
REGULATORY INTELLIGENCE·Warning Letter

NCS Healthcare Glycopyrrolate Recall Highlights Critical Impurity Control Failures for Institutional Supply

NCS Healthcare of Kentucky Inc initiated a Class II recall for 6,929 blister cards of Glycopyrrolate Tabs, USP, 1 mg, due to high out-of-specification results for individual unknown impurities. This event, terminated on February 19, 2021, signals critical quality control deficiencies impacting institutional pharmaceutical supply chains. Procurement and regulatory teams must reassess supplier qualification and product quality assurance protocols for similar drug products.

90-Day Activity
MKMeera Krishnan· Senior Regulatory Intelligence Analyst
2020-02-26